Finance

Beta
Lists
600993:SHA
Mayinglong Pharmaceutical Group Co Ltd
CNÂ¥23.83
+2.19%
(+0.51) 1D
Jun 12, 3:00:04 PM GMT+8  ·   CNY
All symbols
SymbolPriceChange% Change
Generating top insights for 600993...
Open
CNÂ¥23.32
High
CNÂ¥23.84
Low
CNÂ¥23.17
Mkt. cap
10.27B
Avg. vol.
4.47M
Volume
4.73M
P/E ratio
17.40
52-wk high
CNÂ¥30.18
52-wk low
CNÂ¥23.09
EPS
CNÂ¥1.37
Shares outstanding
431.05M
No. of employees
3K
Open
CNÂ¥23.32
High
CNÂ¥23.84
Low
CNÂ¥23.17
Mkt. cap
10.27B
Avg. vol.
4.47M
Volume
4.73M
P/E ratio
17.40
52-wk high
CNÂ¥30.18
52-wk low
CNÂ¥23.09
EPS
CNÂ¥1.37
Shares outstanding
431.05M
No. of employees
3K
News stories
From sources across the web
About Mayinglong Pharmaceutical Group Co Ltd
CEO-
Employees2.54K
Founded1582
Headquarters-
SectorPharmaceutical industry
Websitemayinglong.cn
Previous reportsAll values in CNY
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in CNY
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
979.88M
888.26M
1.03B
1.01B
Cost of goods sold
498.31M
460.66M
521.28M
524.38M
Cost of revenue
498.31M
460.66M
521.28M
524.38M
Research and development expenses
18.46M
20.83M
19.99M
17.06M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
299.78M
232.34M
392.42M
219.69M
Operating expense
327.26M
252.95M
423.97M
243.25M
Total operating expenses
825.57M
713.61M
945.24M
767.64M
Operating income
154.30M
174.65M
84.08M
244.73M
Other non operating income
-6.98M
6.84M
2.12M
-100.17K
EBT including unusual items
173.67M
187.83M
100.89M
255.42M
EBT excluding unusual items
155.98M
200.49M
110.29M
253.57M
Income tax expense
26.33M
25.95M
14.42M
36.14M
Effective tax rate
15.16%
13.81%
14.30%
14.15%
Other operating expenses
11.42M
-8.32M
20.94M
4.28M
Net income
139.65M
157.79M
80.48M
212.59M
Net profit margin
14.25%
17.76%
7.82%
21.00%
Earnings per share
-
-
-
-
Interest and investment income
10.86M
20.70M
26.15M
10.03M
Interest expense
-2.20M
-1.72M
-2.19M
-1.10M
Net interest expenses
8.66M
18.99M
23.96M
8.94M
Depreciation and amortization charges
-
-
-
-
EBITDA
168.26M
185.56M
98.76M
259.41M
Gain or loss from assets sale
216.81K
-216.81K
89.70K
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer